Physician profile
Scott Andes
NPI 1891803037
$14,249.04
in general payments reported to CMS, 2019-2025
50 companies · $2,187 in 2025
The $2,187 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $872 · 2020: $908 · 2021: $3,463 · 2022: $2,891 · 2023: $1,837 · 2024: $2,092 · 2025: $2,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,115.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,547.64 | 2021-2025 | Vraylar, Rinvoq, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,712.11 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Esperion Therapeutics, INC. | $1,515.88 | 2021-2025 | Nexletol |
| Lilly USA, LLC | $876.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $759.77 | 2019-2025 | |
| Novo Nordisk INC | $659.20 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $647.56 | 2021-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $595.09 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $499.45 | 2021-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $399.47 | 2019-2025 | Verquvo |
| Gilead Sciences, INC. | $333.13 | 2019-2024 | |
| Amarin Pharma, INC. | $243.29 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $238.04 | 2019-2022 | |
| Axsome Therapeutics, INC. | $226.99 | 2024-2025 | Symbravo, Auvelity |
| Coloplast Corp | $214.12 | 2023 | Titan |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Andes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.